Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparative Effectiveness of Elranatamab (PF 06863135) in Clinical Study C1071003 Versus Standard of Care (SOC) in a Real-World (RW) External Control Arm of Patients With Triple-Class Refractory (TCR) Multiple Myeloma (MM) From TherapyMonitor MM Germany

NCT06504524 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06504524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06504524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparative Effectiveness of Elranatamab (PF 06863135) in Clinical Study C1071003 Versus Standard of Care (SOC) in a Real-World (RW) External Control Arm of Patients With Triple-Class Refractory (TCR) Multiple Myeloma (MM) From TherapyMonitor MM Germany
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
September 1, 2023
Completion date
May 31, 2024
Enrollment
633 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma